Schedule 13G ownership disclosure

BRIACELL THERAPEUTICS CORP

COMMON STOCK · CUSIP: 107930109

Event date: 2023-12-29

Filing-level shares
818,375.00
Percent of class
5.1%
  • Copia Fund (Cayman) LP

    Shares: 818,375.00 · Class: 5.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001718996-24-000001
Form type
SCHEDULE 13G
Filer
BriaCell Therapeutics Corp.
CIK
CIK 1610820
Filed
Jan 08, 2024
Reporting period
Dec 29, 2023
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub